Gene-edited chickens as bioreactors: systemic risks and ethical dilemmas of industrializing animal protein production for pharmaceuticals

Indigenous and traditional knowledge systems view chickens as sacred beings with roles beyond utility, often integrating them into healing and agricultural practices. For instance, the Navajo (Diné) tradition of 'chicken medicine' uses poultry for holistic health, contrasting with the reductionist approach of gene-editing for pharmaceutical production. These perspectives emphasize reciprocity with animals, which is absent in industrial bioreactor models. Additionally, indigenous communities have long used eggs and poultry for immune support, but their practices are dismissed as 'unscientific' in favor of corporate-driven innovations.

The industrialization of animal agriculture has repeatedly led to zoonotic disease outbreaks, from avian flu to SARS-CoV-2, yet this history is ignored in favor of technological 'solutions.' The 1918 influenza pandemic, linked to poultry farming practices, serves as a cautionary parallel to the risks of mass-producing genetically modified animals. Historically, pharmaceutical production has oscillated between centralized (e.g., Big Pharma) and decentralized (e.g., herbal medicine) models, with the latter often suppressed during colonial and industrial eras. The current push for chicken bioreactors echoes 20th-century efforts to industrialize insulin production via E. coli, which later faced ethical and supply chain crises.

In many cultures, chickens are not merely 'bioreactors' but integral to communal health and spiritual practices. For example, in Hindu traditions, chickens are offered in rituals to appease deities for healing, reflecting a non-utilitarian relationship with animals. African and Indigenous American communities have used poultry for centuries to bolster immunity, often through fermented egg preparations, which are now being 'reinvented' as 'biotech.' Meanwhile, in Japan, 'medicinal eggs' (yak eggs) are consumed for health, but their production is artisanal, contrasting with the industrial scale proposed by gene-editing. These diverse practices highlight the cultural blind spots in Western-centric biotech narratives.

While gene-editing (e.g., CRISPR) can theoretically produce therapeutic proteins in eggs, the scientific literature highlights significant challenges, including off-target effects, unintended ecological consequences, and the potential for horizontal gene transfer to wild poultry populations. Studies on avian influenza transmission in industrial farms raise concerns about the safety of mass-producing GM poultry. Additionally, the economic viability of this approach is unproven, with past bioreactor models (e.g., goat-produced antithrombin) facing high costs and regulatory hurdles. The scientific community has also warned about the ethical risks of normalizing animal commodification for medical production.

Artistic and spiritual traditions often frame animals as co-creators in healing, rather than passive vessels for human benefit. For example, the Japanese art of 'egg divination' (tamago uranai) treats eggs as symbolic and prophetic, challenging the reductionist view of poultry as bioreactors. In Sufi poetry, chickens symbolize divine providence and interconnectedness, a stark contrast to the industrial logic of turning them into pharmaceutical factories. Meanwhile, contemporary art movements like 'bioart' critique the ethical boundaries of genetic manipulation, using chickens as symbols of resistance against biocapitalism. These perspectives reveal the spiritual and creative dimensions erased by technocratic narratives.

If scaled, gene-edited chicken bioreactors could lead to corporate monopolies on medical protein production, exacerbating global health inequities by making essential drugs unaffordable for low-income populations. Scenario modeling suggests that such systems could increase zoonotic disease risks, as seen in the rise of avian flu in industrial poultry farms. Alternatively, decentralized models—such as community-owned egg-based antibody production—could democratize access to medical proteins while reducing ecological footprints. The long-term implications include the potential for 'pharmaceutical sovereignty' movements, where communities reclaim control over medical production from corporate entities.

Small-scale farmers, particularly in the Global South, are sidelined in this narrative despite their role in sustainable poultry farming and traditional medicine. Indigenous communities, whose knowledge of animal-based healing is often co-opted without credit, are excluded from decision-making about genetic technologies. Women, who dominate backyard poultry farming in many cultures, are rendered invisible in favor of corporate and academic 'experts.' Additionally, animal welfare advocates and ethicists critical of industrial animal bioreactors are marginalized in mainstream discussions, which prioritize technological 'progress' over ethical and social justice concerns.